Denali Therapeutics Inc. DNLI Interest Income
Interest Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s interest income?
- Denali Therapeutics Inc. (DNLI) reported interest income of $8.91M in Q1 2026.
- How has Denali Therapeutics Inc.'s interest income changed year-over-year?
- Denali Therapeutics Inc.'s interest income decreased by 29.3% year-over-year, from $12.61M to $8.91M.
- What is the long-term trend for Denali Therapeutics Inc.'s interest income?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s interest income has grown at a 42.7% compound annual growth rate (CAGR), from $14.77M to $42.9M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.